Cost-effectiveness of Encorafenib with Binimetinib in Unresectable or Metastatic BRAF-mutant Melanoma

Overview

Journal Eur J Health Econ

Specialty Health Services

Date 2023 Jul 11

PMID 37433888

Authors

Jean-Baptiste Trouiller

Georgios F Nikolaidis

Berengere Macabeo

Nicolas Meyer

Laetitia Gerlier

Max Schlueter

Philippe Laramee

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to determine the cost-effectiveness of encorafenib with binimetinib (EncoBini) as compared to other targeted double combination therapies, namely dabrafenib with trametinib (DabraTrame) and vemurafenib with cobimetinib (VemuCobi), for the treatment of BRAF V600-mutant unresectable or metastatic melanoma (MM) from the French payer perspective.

Methods: A partitioned survival model was developed considering a lifetime horizon. The model structure simulated the clinical pathway of patients with BRAF V600-mutant MM. Clinical effectiveness and safety inputs were sourced from the COLUMBUS trial, a network meta-analysis and published literature. Costs, resource use, and the quality of life inputs were obtained from the literature and appropriate French sources.

Results: Over a lifetime horizon, EncoBini was associated, on average, with reduced costs and increased quality adjusted life years (QALYs), dominating both targeted double combination therapies. For a willingness-to-pay threshold of €90,000 per QALY, the probability of EncoBini being cost-effective against either comparator remained above 80%. The most influential model parameters were the hazard ratios for the overall survival of EncoBini vs DabraTrame and VemuCobi, the pre- and post-progression utility values, as well as treatment dosages and the relative dose intensity of all interventions.

Conclusion: EncoBini is associated with reduced costs and increased QALYs, dominating other targeted double combination therapies (DabraTrame, VemuCobi) for patients with BRAF V600-mutant MM in France. EncoBini is a highly cost-effective intervention in MM.

References

Miller A, Mihm Jr M . Melanoma. N Engl J Med. 2006; 355(1):51-65. DOI: 10.1056/NEJMra052166. View

Potrony M, Badenas C, Aguilera P, Puig-Butille J, Carrera C, Malvehy J . Update in genetic susceptibility in melanoma. Ann Transl Med. 2015; 3(15):210. PMC: 4583600. DOI: 10.3978/j.issn.2305-5839.2015.08.11. View

Ryu S, Youn C, Moon A, Howland A, Armstrong C, Song P . Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Med J. 2017; 53(3):173-177. PMC: 5636755. DOI: 10.4068/cmj.2017.53.3.173. View

Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U . Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v126-32. DOI: 10.1093/annonc/mdv297. View

Serra-Arbeloa P, Rabines-Juarez A, Alvarez-Ruiz M, Guillen-Grima F . Cost of Cutaneous Melanoma by Tumor Stage: A Descriptive Analysis. Actas Dermosifiliogr. 2016; 108(3):229-236. DOI: 10.1016/j.ad.2016.09.010. View

Vouk K, Benter U, Amonkar M, Marocco A, Stapelkamp C, Pfersch S . Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. J Med Econ. 2016; 19(9):900-12. DOI: 10.1080/13696998.2016.1184155. View

Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G . Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):603-615. DOI: 10.1016/S1470-2045(18)30142-6. View

Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G . Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19(10):1315-1327. DOI: 10.1016/S1470-2045(18)30497-2. View

Ascierto P, Dummer R, Gogas H, Flaherty K, Arance A, Mandala M . Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020; 126:33-44. DOI: 10.1016/j.ejca.2019.11.016. View

10.

Long G, Eroglu Z, Infante J, Patel S, Daud A, Johnson D . Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 2017; 36(7):667-673. PMC: 10466457. DOI: 10.1200/JCO.2017.74.1025. View

11.

Ascierto P, McArthur G, Dreno B, Atkinson V, Liszkay G, Di Giacomo A . Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; 17(9):1248-60. DOI: 10.1016/S1470-2045(16)30122-X. View

12.

Seth R, Messersmith H, Kaur V, Kirkwood J, Kudchadkar R, McQuade J . Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020; 38(33):3947-3970. DOI: 10.1200/JCO.20.00198. View

13.

Corrie P, Meyer N, Berardi R, Guidoboni M, Schlueter M, Kolovos S . Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Cancer Treat Rev. 2022; 110:102463. DOI: 10.1016/j.ctrv.2022.102463. View

14.

Cai C, Yunusa I, Tarhini A . Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma. JAMA Netw Open. 2021; 4(11):e2132262. PMC: 8586909. DOI: 10.1001/jamanetworkopen.2021.32262. View

15.

Balch C, Gershenwald J, Soong S, Thompson J, Atkins M, Byrd D . Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-206. PMC: 2793035. DOI: 10.1200/JCO.2009.23.4799. View

16.

Dreno B, Ribas A, Larkin J, Ascierto P, Hauschild A, Thomas L . Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017; 28(5):1137-1144. DOI: 10.1093/annonc/mdx040. View

17.

Hoch J, Briggs A, Willan A . Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002; 11(5):415-30. DOI: 10.1002/hec.678. View

18.

Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M . Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005; 14(4):339-47. DOI: 10.1002/hec.985. View

19.

Lacy K, Karagiannis S, Nestle F . Advances in the treatment of melanoma. Clin Med (Lond). 2012; 12(2):168-71. PMC: 4954106. DOI: 10.7861/clinmedicine.12-2-168. View

20.

Majem M, Manzano J, Marquez-Rodas I, Mujika K, Munoz-Couselo E, Perez-Ruiz E . SEOM clinical guideline for the management of cutaneous melanoma (2020). Clin Transl Oncol. 2021; 23(5):948-960. PMC: 8057998. DOI: 10.1007/s12094-020-02539-9. View